Novartis invests $180 million in Singapore facility

Novartis Pharma recently announced that it plans to invest $180 million in a new pharmaceutical production facility in Singapore, providing additional needed capacity within its global manufacturing network.

Novartis Pharma recently announced that it plans to build a new pharmaceutical production facility in Singapore, providing additional needed capacity within its global manufacturing network.

The facility will produce tablets for the global market. Construction is expected to begin in late 2004, with operations beginning in 2007. Novartis will invest approximately $180 million in the project, which includes building and equipment, leasing of land, a distribution centre and start-up costs.

According to a statement, the focus of the Singapore plant will be on bulk production of new and existing Novartis products. When fully operational in 2008, the plant and distribution centre are expected to employ more than 150 people.

Novartis added that the latest investment will strengthen its presence in Singapore. Novartis established its Institute for Tropical Diseases (NITD) in Singapore last year and its CIBA Vision Business Unit is in the process of building a contact lens manufacturing facility there.

On the web